Literature DB >> 16626811

IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles.

C Malmeström1, B A Andersson, S Haghighi, J Lycke.   

Abstract

Biological markers would provide valuable tools for tracking disease activity, immunopathological processes or therapeutic efficacy in MS. In this study we analysed a panel of Th(1)/Th(2) cytokines and the chemokine CCL2 in serum and CSF from MS patients and healthy controls. Increased levels of IL-6 (p<0.05) and decreased levels of CCL2 (p<0.001), with the lowest levels during acute relapses, was found in CSF from patients with relapsing-remitting MS. CSF levels of CCL2 correlated with indices for intrathecal IgG production and the CSF level of the neurofilament light protein, a marker for axonal damage, indicating a immunopathogenic role for CCL2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16626811     DOI: 10.1016/j.jneuroim.2006.03.004

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  19 in total

1.  Central inflammation versus peripheral regulation in multiple sclerosis.

Authors:  L J Edwards; B Sharrack; A Ismail; H Tumani; C S Constantinescu
Journal:  J Neurol       Date:  2011-03-09       Impact factor: 4.849

Review 2.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Authors:  Soudeh Ghafouri-Fard; Kasra Honarmand; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2021-01-06       Impact factor: 3.584

Review 3.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

Review 4.  Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.

Authors:  Sara J Ireland; Nancy L Monson; Laurie S Davis
Journal:  Cytokine       Date:  2015-03-17       Impact factor: 3.861

5.  Myelin basic protein induces inflammatory mediators from primary human endothelial cells and blood-brain barrier disruption: implications for the pathogenesis of multiple sclerosis.

Authors:  T G D'Aversa; E A Eugenin; L Lopez; J W Berman
Journal:  Neuropathol Appl Neurobiol       Date:  2013-04       Impact factor: 8.090

Review 6.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

7.  Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis.

Authors:  Jian Hong; Haiyan Li; Meiyue Chen; Ying C Q Zang; Sheri M Skinner; James M Killian; Jingwu Z Zhang
Journal:  Int Immunol       Date:  2009-10-11       Impact factor: 4.823

Review 8.  Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression.

Authors:  Michele L Pucak; Katherine A L Carroll; Douglas A Kerr; Adam I Kaplin
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

Review 9.  Targeting interleukin-6 for noninfectious uveitis.

Authors:  Phoebe Lin
Journal:  Clin Ophthalmol       Date:  2015-09-11

Review 10.  Interleukin-6, a major cytokine in the central nervous system.

Authors:  María Erta; Albert Quintana; Juan Hidalgo
Journal:  Int J Biol Sci       Date:  2012-10-25       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.